We are live on ! Find out more
OM icon

Outset Medical

122 hedge funds and large institutions have $187M invested in Outset Medical in 2024 Q2 according to their latest regulatory filings, with 32 funds opening new positions, 32 increasing their positions, 37 reducing their positions, and 24 closing their positions.

New
Increased
Maintained
Reduced
Closed

66% more capital invested

Capital invested by funds: $113M → $187M (+$74.2M)

54% more call options, than puts

Call options by funds: $1.03M | Put options by funds: $673K

33% more first-time investments, than exits

New positions opened: 32 | Existing positions closed: 24

7% more funds holding

Funds holding: 114122 (+8)

0.4% less ownership

Funds ownership: 6.67%6.26% (-0.4%)

14% less repeat investments, than reductions

Existing positions increased: 32 | Existing positions reduced: 37

Holders
122
Holders Change
+8
Holders Change %
+7.02%
% of All Funds
1.76%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
32
Increased
32
Reduced
37
Closed
24
Calls
$1.03M
Puts
$673K
Net Calls
+$362K
Net Calls Change
+$150K
Name Holding Trade Value Shares
Change
Change in
Stake
Jacobs Levy Equity Management
26
Jacobs Levy Equity Management
New Jersey
$1.53M -$5.88K -120 -0.5%
Northern Trust
27
Northern Trust
Illinois
$1.49M -$106K -2,155 -8%
Marshall Wace
28
Marshall Wace
United Kingdom
$1.21M +$852K +17,383 +488%
Charles Schwab
29
Charles Schwab
California
$1.14M -$354K -7,229 -27%
Citadel Advisors
30
Citadel Advisors
Florida
$1.13M +$37.6K +768 +4%
Susquehanna International Group
31
Susquehanna International Group
Pennsylvania
$1.11M +$838K +17,103 +801%
Two Sigma Advisers
32
Two Sigma Advisers
New York
$1.04M -$677K -13,814 -43%
Point72 Asset Management
33
Point72 Asset Management
Connecticut
$827K +$702K +14,327 New
State Street
34
State Street
Massachusetts
$809K -$2.61M -53,286 -79%
Qube Research & Technologies (QRT)
35
Qube Research & Technologies (QRT)
United Kingdom
$801K +$556K +11,343 +448%
Walleye Capital
36
Walleye Capital
New York
$799K +$222K +4,521 +49%
SPS
37
Susquehanna Portfolio Strategies
Pennsylvania
$788K -$20.9K -427 -3%
CSS
38
Cubist Systematic Strategies
Connecticut
$774K +$456K +9,316 +228%
Los Angeles Capital Management
39
Los Angeles Capital Management
California
$731K +$620K +12,652 New
Tudor Investment Corp
40
Tudor Investment Corp
Connecticut
$695K +$14.5K +295 +3%
Two Sigma Investments
41
Two Sigma Investments
New York
$641K -$1.44M -29,422 -73%
Federated Hermes
42
Federated Hermes
Pennsylvania
$638K
PP
43
PDT Partners
New York
$556K -$45.5K -928 -9%
AQR Capital Management
44
AQR Capital Management
Connecticut
$548K -$159K -3,250 -26%
Dimensional Fund Advisors
45
Dimensional Fund Advisors
Texas
$548K -$140K -2,863 -23%
HF
46
HRT Financial
New York
$531K +$451K +9,205 New
YIH
47
Y-Intercept (HK)
Hong Kong
$489K +$415K +8,472 New
GCP
48
GSA Capital Partners
United Kingdom
$418K -$1.41M -28,806 -80%
GAM
49
Griffin Asset Management
New York
$406K +$24.8K +506 +8%
Bank of America
50
Bank of America
North Carolina
$366K -$356K -7,258 -53%

OM Hedge Fund Activity: Q2 2024 in Review

122 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Outset Medical (OM) for Q2 2024, worth a combined $187M — up 66% from $113M a quarter earlier.

Buyers outnumbered sellers: 32 funds opened new OM positions and 24 closed out — a net gain of 8 holders — while 32 added to existing stakes and 37 trimmed.

The largest buyer was GMT Capital, opening a new position worth an estimated $4.81M. The largest seller was BlackRock, cutting an estimated $7.79M.

  • 122 institutional investors held Outset Medical (OM) as of Q2 2024, up from 114 in Q1 2024.
  • Funds reported $187M of Outset Medical stock for Q2 2024, up 66% quarter-over-quarter.
  • 32 funds opened new Outset Medical positions in Q2 2024 and 24 closed out, a net change of +8 holders.
  • The largest Outset Medical buyer in Q2 2024 was GMT Capital, an estimated $4.81M added.
  • The largest Outset Medical seller in Q2 2024 was BlackRock, an estimated $7.79M sold.

Based on aggregated 13F filings for Q2 2024.